Takeda v. Teva: Consent Judgment Blocks Teva's Generic Ponatinib ANDA in 251 Days
Takeda Pharmaceuticals and Ariad Pharmaceuticals sued Teva over four patents covering ponatinib crystalline forms and kinase inhibitor compounds in the District of New Jersey. The case resolved in a court-entered consent judgment that permanently enjoins Teva from commercialising its ANDA product until all four patents-in-suit expire.
Takeda secures permanent injunction over generic ponatinib via consent judgment
On 21 December 2022, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals U.S.A., Inc., and Ariad Pharmaceuticals, Inc. (collectively, Takeda) filed suit in the District of New Jersey against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries Limited. The complaint alleged infringement of six patents, with the consent judgment ultimately identifying four patents-in-suit — US9,493,470; US11,192,895; US11,192,897; and US11,384,086 — covering crystalline forms of ponatinib (a kinase inhibitor oncology drug) and its monohydrochloride salt. The trigger was Teva's filing of Abbreviated New Drug Application No. 217825, referencing Takeda's NDA No. 203469.
The recorded basis of termination is a Consent Judgment, entered by the court on 29 August 2023. The docket order, styled as a stipulated consent judgment, permanently enjoins Teva and its successors from making, using, selling, importing, or distributing the Teva ANDA Product or any ponatinib-containing drug product referencing NDA No. 203469 in the United States until expiration of all four patents-in-suit, except as specifically authorised by Takeda. The court retained jurisdiction to enforce the consent judgment. All claims, counterclaims, and affirmative defences were dismissed with prejudice, with no costs or fees awarded to either party.
Resolution in 251 days — before any claim construction or substantive discovery rulings — is consistent with Hatch-Waxman litigation patterns where brand-generic negotiations conclude early. What drove the parties to agree, and whether any authorisation or permitted entry date forms part of their arrangement, is not disclosed in the publicly available record. Teva's Paragraph IV certification is expressly preserved, and FDA approval of ANDA No. 217825 is not restricted, meaning the ANDA may proceed through regulatory channels independently of the injunction.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 251 days
From filing to consent judgment — under 9 months in the D.N.J.
US9,493,470 and three continuation patents — ponatinib crystalline forms
Any pharmaceutical developer, ANDA applicant, or contract manufacturer working with ponatinib or structurally related BCR-ABL kinase inhibitors should treat this patent family as a high-priority FTO target. The consent judgment demonstrates that Takeda will move quickly and seek injunctive relief — and the layered crystalline form coverage means that selecting a different polymorphic form of the API does not automatically clear the estate. Formulation teams and regulatory affairs groups advancing ponatinib-referencing ANDAs need a detailed claim mapping before any ANDA filing decision.
Official order — verbatim text
The consent judgment is a stipulated, court-entered order — not a contested ruling. It binds Teva by permanent injunction across all four patents-in-suit, with the court retaining enforcement jurisdiction. The express dismissal of all claims and counterclaims with prejudice closes the litigation record, while the Paragraph IV preservation and FDA approval carve-outs suggest the parties negotiated carefully around regulatory optionality. The specific commercial terms of any underlying arrangement are not disclosed in the available record.
Consent judgment: what the agreed resolution means for both parties
A binding, court-entered judgment on agreed terms
A consent judgment is not merely a settlement agreement — it is a formal court order carrying the full enforcement power of the judiciary. Here, the parties stipulated to its terms and the District of New Jersey entered it on 29 August 2023. The court expressly retained jurisdiction to enforce the judgment and resolve any related disputes, making any future breach directly actionable as contempt.
Court-entered, fully enforceablePermanent injunction secures Takeda's ponatinib exclusivity
Takeda obtained a permanent injunction blocking Teva from commercialising any ponatinib-containing ANDA product referencing NDA No. 203469 across all four patents-in-suit until their expiration. Enforcement rights pass to Takeda's successors and assigns, providing durable protection. The consent judgment also confirms court jurisdiction over future enforcement — a material advantage if compliance issues arise.
Injunction until patent expiryTeva enjoined but ANDA and Paragraph IV preserved
Teva is permanently enjoined from commercialising its ANDA product in the United States until the four patents-in-suit expire. However, the consent judgment expressly preserves Teva's Paragraph IV certification against those patents and does not restrict FDA from approving ANDA No. 217825. This means Teva retains the regulatory approval pathway and the ability to launch if the patent position changes — though the specific terms of any commercial arrangement are not disclosed in the public record.
Enjoined; ANDA approval preservedPonatinib market exclusivity reinforced across four patent layers
With injunctions covering four patents protecting different aspects of ponatinib's crystalline form and salt, Takeda has erected a multi-layered IP barrier against this generic entrant. For other ANDA filers or follow-on generic developers, the consent judgment signals Takeda's willingness to enforce aggressively and quickly. The preserved Paragraph IV certification leaves open the possibility of future challenge or negotiated entry, but no such terms are visible in the public record.
Multi-patent exclusivity reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Takeda Pharmaceuticals America, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Takeda Pharmaceuticals U.S.A., Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Ariad Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Defendant | Teva Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries Limited | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian John Forsatz | Attorney | Counsel for Takeda Pharmaceuticals America, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for Takeda Pharmaceuticals America, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Takeda Pharmaceuticals America, Inc.Search in Eureka ↗ |
| Plaintiff law firm | QUINN EMANUEL URQUHART & SULLIVAN LLC | Law Firm | Representing Takeda Pharmaceuticals America, Inc.Search in Eureka ↗ |
| Defendant counsel | Christine Intromasso Gannon | Attorney | Counsel for Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Giancarlo Scaccia | Attorney | Counsel for Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Lauren Ruth Malakoff | Attorney | Counsel for Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Greenberg Traurig PA | Law Firm | Representing Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Walsh Pizzi O'reilly Falanga, LLP | Law Firm | Representing Teva Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the ponatinib and kinase inhibitor patent space
Forward-looking patent and R&D intelligence derived from Takeda's and Teva's IP activity in the BCR-ABL kinase inhibitor and oncology crystalline form space.
Takeda's continuation filing strategy around ponatinib crystalline forms
Three of the four patents-in-suit are continuation applications filed in the US17-series off a common priority chain. This pattern — filing multiple continuation patents from a single parent — is a hallmark of lifecycle management in branded pharma. Mapping Takeda's pending continuation applications in this family may reveal additional forthcoming patents that could extend ponatinib exclusivity further than current expiry dates suggest.
Continuation portfolio watchPatent filing trends in BCR-ABL kinase inhibitor solid-state chemistry
Crystalline form and polymorphism patents around kinase inhibitors for CML and ALL treatment have become an active filing area as base compound patents approach expiry. Tracking recent PCT and US applications in the imidazo[1,2-b]pyridazine compound class can reveal which competitors are positioning new solid-state formulations — and where white space exists for alternative form development outside Takeda's claimed scope.
Kinase inhibitor form filingsTeva's kinase inhibitor and oncology ANDA patent landscape
Teva preserved its Paragraph IV certification and FDA ANDA approval pathway despite the injunction. Monitoring Teva's patent challenges — including any IPR petitions filed at the PTAB against the ponatinib patent family — can signal when and whether Teva intends to re-enter the ponatinib market. Teva's broader oncology ANDA filing history also indicates which other branded kinase inhibitor franchises it is targeting.
Teva ANDA & IPR activityAdjacent R&D opportunities near the imidazo[1,2-b]pyridazine scaffold
The patents-in-suit focus on specific crystalline forms and salt forms of the ponatinib molecule. Adjacent opportunities may exist in novel co-crystal forms, amorphous dispersions, or next-generation BCR-ABL inhibitors with distinct scaffolds that fall outside the claimed compound and form space. Patent landscape analysis around the imidazo[1,2-b]pyridazine class can surface freedom-to-operate zones for novel kinase inhibitor candidates.
Kinase inhibitor white spaceSimilar Hatch-Waxman ponatinib and kinase inhibitor patent cases
Explore patent infringement actions in the District of New Jersey involving crystalline form pharmaceutical patents and Hatch-Waxman ANDA challenges to kinase inhibitor oncology drugs.
What this case signals for the Hatch-Waxman oncology IP landscape
Consent judgments with permanent injunctions are a high-stakes tool in branded pharma's ANDA defence arsenal — and Takeda deployed it with speed.
Speed of resolution signals strong Takeda IP position or early negotiation leverage
A 251-day resolution before any substantive court rulings is consistent with a defendant reassessing its invalidity or non-infringement position early. For IP teams monitoring branded pharma enforcement, rapid consent judgments across multiple patents suggest the originator perceived its portfolio as defensible enough to demand injunctive relief without going to trial.
Four-patent coverage over ponatinib forms raises the bar for future ANDA challengers
The patents-in-suit cover crystalline forms and kinase inhibitor compound variations — not just the base molecule. Generic entrants or biosimilar developers working in the BCR-ABL kinase inhibitor space should conduct FTO analysis across all four patent families before advancing an ANDA or NDA strategy. A single overlooked crystalline form patent can trigger an injunction that blocks launch entirely.
Takeda v Teva — key questions answered
The case ended in a consent judgment entered by the District of New Jersey on 29 August 2023 — 251 days after filing. Teva is permanently enjoined from commercialising its ANDA product (ANDA No. 217825) in the United States until expiration of all four patents-in-suit: US9,493,470; US11,192,895; US11,192,897; and US11,384,086. All claims were dismissed with prejudice and no costs were awarded to either party.
The complaint involved six patents. The consent judgment identifies four patents-in-suit: US9,493,470; US11,192,895; US11,192,897; and US11,384,086, all covering crystalline forms of ponatinib and its monohydrochloride salt. Two additional patents listed in the case — US8,114,874 and US9,029,533 — cover substituted acetylenic imidazo[1,2-b]pyridazine kinase inhibitor compounds more broadly.
Teva is permanently enjoined from making, using, selling, offering to sell, or importing its ANDA product or any ponatinib-containing product referencing NDA No. 203469 in the United States until the four patents-in-suit expire. However, the consent judgment expressly preserves Teva's Paragraph IV certification against those patents and does not restrict FDA from approving ANDA No. 217825. The specific terms of any commercial arrangement between the parties are not disclosed in the public record.
Ariad Pharmaceuticals, Inc. is listed as a co-plaintiff alongside Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals U.S.A., Inc. This suggests Ariad holds ownership or licensed rights in one or more of the patents-in-suit covering ponatinib and related kinase inhibitor compounds. The specific ownership or licensing arrangement between Ariad and Takeda is not detailed in the publicly available record.
A consent judgment is a formal court order — not merely a private agreement — entered on terms stipulated by the parties. Unlike a confidential settlement, it appears on the docket, is publicly enforceable, and gives the court retained jurisdiction to resolve compliance disputes. In Hatch-Waxman litigation, consent judgments typically include injunctions against generic commercialisation. Here, the court entered the order on 29 August 2023 and expressly retained jurisdiction to enforce it. Any underlying commercial arrangements between Takeda and Teva are not disclosed in the public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.